CLACKAMAS, Ore., Oct. 15, 2019 /PRNewswire/ -- Today, Oregon-based Health Wright Products (HWP) announced the completion of phase one of i

MENLO PARK, Calif., Oct. 15, 2019 /PRNewswire/ -- Subtle Medical, a healthcare technology company focused on improving the quality, efficiency, and accessibility of medical imaging, announced today 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtleMRTM. SubtleMR is an image processing software that uses denoising and resolution

Nextleaf Labs is designed to process more than 270,000 kg of dried cannabis and hemp biomass per year using Nextleaf Solutions' patented intellectual property VANCOUVER, Oct. 15, 2019 /PRNewswire/ - Nextleaf Solutions Ltd. ("Nextleaf", "OILS", or the "Company") (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) a

DUBLIN, Oct. 15, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that it will release its third quarter calendar year 2019 financial results on Wednesday, November 6, 2019. The Company will host a conference call beginning at 8:00 a.m. (EDT).

Strainprint Analytics Research Platform to Help Support Canadian Government Policies Post-Cannabis Legalization TORONTO, Oct. 15, 2019 /PRNewswire/ -

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 /PRNewswire/ -- Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of fibrosis, announced the publication of a study evaluating the use of a positron emission tomography (PET) tracer for the detection of idiopathic pulmonary fibrosis

DAVIS, Calif., Oct. 15, 2019 /PRNewswire/ -- The National Institute on Drug Abuse (NIDA) has awarded a grant to EicOsis LLC as part of the NIH initiati

REDWOOD SHORES, Calif., Oct. 15, 2019 /PRNewswire/ -- Taking a new people-centric approach to providing support and care, Oracle offers new services to citizens in need. New digital case management capabilities, now available in

SAN FRANCISCO, Oct. 15, 2019 /PRNewswire/ -- Castlight Health, Inc. (NYSE: CSLT) will release its third quarter 2019 financial results on Thursday, October 24, 2019, after the market close. At 5:00 p.m. Eastern Time (ET), senior management will host a conference call to review the Company's financial performance

NEW YORK, Oct. 15, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today reported top-line data from REL-1017-202, a double-blind, placebo-controlled Phase 2 clinical study evaluating the safety, tolerability and efficacy of two doses of REL-101